StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$8.56−0.64 (-6.96%)

Close on Nov 18, 2026Market cap $764.38MP/E –Yield –

Syndax Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Syndax Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$178.64M. For fiscal 2025 it was -$273.08M. The highest annual figure on record is $26.22M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$273.08M–
FY2024Dec 31, 2024-$339.67M–
FY2023Dec 31, 2023-$229.95M–
FY2022Dec 31, 2022-$151.76M-678.8%
FY2021Dec 31, 2021$26.22M–
FY2020Dec 31, 2020-$71.42M–
FY2019Dec 31, 2019-$57.54M–
FY2018Dec 31, 2018-$75.88M–
FY2017Dec 31, 2017-$61.95M–
FY2016Dec 31, 2016-$43.77M–
FY2015Dec 31, 2015-$20.51M–
FY2014Dec 31, 2014-$21.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$41.90M–
Q2 FY2026Jun 30, 2026-$40.00M–
Q1 FY2026Mar 31, 2026-$34.20M–
Q4 FY2025Dec 31, 2025-$62.55M–
Q3 FY2025Sep 30, 2025-$57.43M–
Q2 FY2025Jun 30, 2025-$69.35M–
Q1 FY2025Mar 31, 2025-$83.76M–
Q4 FY2024Dec 31, 2024-$96.37M–
Q3 FY2024Sep 30, 2024-$89.58M–
Q2 FY2024Jun 30, 2024-$74.22M–
Q1 FY2024Mar 31, 2024-$79.51M–
Q4 FY2023Dec 31, 2023-$77.91M–
Q3 FY2023Sep 30, 2023-$56.36M–
Q2 FY2023Jun 30, 2023-$49.68M–
Q1 FY2023Mar 31, 2023-$46.02M–
Q4 FY2022Dec 31, 2022-$42.03M-143.9%
Q3 FY2022Sep 30, 2022-$35.14M–
Q2 FY2022Jun 30, 2022-$37.72M–
Q1 FY2022Mar 31, 2022-$36.86M–
Q4 FY2021Dec 31, 2021$95.75M–
Q3 FY2021Sep 30, 2021-$20.03M–
Q2 FY2021Jun 30, 2021-$22.33M–
Q1 FY2021Mar 31, 2021-$27.16M–
Q4 FY2020Dec 31, 2020-$19.86M–
Q3 FY2020Sep 30, 2020-$19.85M–
Q2 FY2020Jun 30, 2020-$16.61M–
Q1 FY2020Mar 31, 2020-$15.10M–
Q4 FY2019Dec 31, 2019-$14.21M–
Q3 FY2019Sep 30, 2019-$13.15M–
Q2 FY2019Jun 30, 2019-$15.37M–
Q1 FY2019Mar 31, 2019-$14.81M–
Q4 FY2018Dec 31, 2018-$19.33M–
Q3 FY2018Sep 30, 2018-$17.84M–
Q2 FY2018Jun 30, 2018-$18.95M–
Q1 FY2018Mar 31, 2018-$19.75M–
Q4 FY2017Dec 31, 2017-$19.49M–
Q3 FY2017Sep 30, 2017-$15.45M–
Q2 FY2017Jun 30, 2017-$13.84M–
Q1 FY2017Mar 31, 2017-$13.18M–
Q4 FY2016Dec 31, 2016-$11.14M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?